A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus

doi:10.3748/wjg.v17.i38.4321

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 38

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7099)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-2) series.

Item

Count

PDF

505

HTML

6308

Figures (1-7)

143

Tables (1-2)

143

Sum=7099

Oct 14, 2011 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (100)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 14, 2011; 17(38): 4321-4333
Published online Oct 14, 2011. doi: 10.3748/wjg.v17.i38.4321

Table 1 General information of included randomized controlled trials

First author, year^[Ref.]	Group (n)	Interventions on mothers	Maternal HBV DNA level¹		Newborns within 24 h			Infants within 6-12 mo			Adverse events
			Before intervention	Before delivery	HBsAg(+)	HBeAg(+)	HBV DNA (+)	HBsAg(+)	HBeAg(+)	HBV DNA (+)	Mothers	Infants
Zhang, 2010[21]	Arm 1:50	3TC 100 mg od from week 28	6.83 ± 0.90	3.65 ± 0.54	6/50	-	5/50	1/50	-	1/50	0	0
	Arm 2:50	No treatment	6.87 ± 1.67	6.88 ± 1.08	17/50	-	18/50	8/50	-	8/50	-	-
Han, 2010[22]	Arm 1:52	3TC 100 mg od from week 20	-	-	5/52	-	1/52	0/42	-	0/42	0	0
	Arm 2:61	200 IU HBIG every 2 wk from week 28	-	-	26/61	-	7/61	9/55	-	9/55	0	0
Han, 2009[23]	Arm 1:57	3TC 100 mg od from week 20	7.5 ± 0.50	-	6/57	-	1/57	0/46	-	0/46	0	0
	Arm 2:66	200 IU HBIG every 2 wk from week 28	7.5 ± 0.72	-	27/66	-	8/66	10/59	-	10/59	0	1/66
Su, 2009[24]	Arm 1:128	3TC 100 mg od from week 32, 200 IU HBIG at week 28, 32, 36	-	-	-	-	-	6/128	-	-	0	0
	Arm 2:120	200 IU HBIG at week 28, 32, 36	-	-	-	-	-	17/120	-		-	-
Xu, 2009[25]	Arm 1:63	3TC 100 mg od from week 32	9.35 ± 0.21	7.71 ± 1.49	17/5	-	7/56	10/56	-	11/56	7/89	10/56
	Arm 2:62	Placebo	9.43 ± 0.21	9.34 ± 0.22	14/59	-	24/59	23/59	-	27/59	6/61	12/59
Shi, 2009[26]	Arm 1:49	3TC 100 mg od from week 28	7.24 ± 1.90	4.49 ± 3.25	3/49	-	1/49	-	-	-	2/51	-
	Arm 2:116	100 IU HBIG at week 28, 32, 36	6.31 ± 2.13	5.86 ± 2.62	8/116	-	4/116	-	-	-	3/146	-
	Arm 3:43	Placebo	6.40 ± 2.12	6.19 ± 2.57	10/43	-	5/43	-	-	-	2/84	-
Yang, 2008[27]	Arm 1:45	3TC 100 mg od from week 24	6.99 ± 0.84	5.10 ± 0.80	-	-	-	1/45	-	-	-	0
	Arm 2:42	100 IU HBIG at week 28, 32, 36	6.87 ± 0.92	6.87 ± 0.92	-	-	-	6/42	-	-	-	0
Guo, 2008[28]	Arm 1:70	3TC 100 mg od from week 28	-	-	6/70	-	8/70	4/70	-	6/70	-	-
	Arm 1:40	No treatment	-	-	10/40	-	13/40	12/40	-	18/40	-	-
Xiang, 2007[29]	Arm 1:21	3TC 100 mg od from week 28	8.02 ± 1.15	4.58 ± 1.22	1/21	3/21	-	-	-	-	-	-
	Arm 2:25	200 IU HBIG every month from month 4	7.63 ± 1.23	5.12 ± 1.07	2/25	2/25	-	-	-	-	-	-
	Arm 3:18	No treatment	7.16 ± 0.79	6.88 ± 1.36	5/18	3/18	-	-	-	-	-	-
Feng, 2007[30]	Arm 1:48	3TC 100 mg od from week 28	8.34 ± 1.23	4.85 ± 1.27	8/48		9/48	7/48	-	7/48	0	0
	Arm 1:42	No treatment	8.26 ± 1.87	8.56 ± 1.08	17/42		19/42	16/42	-	16/42	0	0
Li, 2006[31]	Arm 1:36	3TC 100 mg od from week 24	6.89 ± 0.82	5.08 ± 0.76	-	-	-	1/36	-	-	0	0
	Arm 2:44	No treatment	> 5.00	> 5.00	-	-	-	7/44	-	-	0	0
Li, 2006[32]	Arm 1:40	3TC 100 mg od from week 28 and 200 IU HBIG at week 28, 32, 36	-	-	-	-	-	1/35	1/35	1/35	0	0
	Arm 2:37	200 IU HBIG at week 28, 32, 36	-	-	-	-	-	7/32	6/32	6/32	0	0
Han, 2005[33]	Arm 1:43	3TC 100 mg od from week 28	7.15 ± 0.91	5.43 ± 0.85	-	-	-	0/43	-	0/43	0	0
	Arm 1:35	No treatment	> 5.60	> 5.60	-	-	-	5/35	-	-	0	0
Shi, 2005[34]	Arm 1:21	3TC 100 mg od from week 28	8.72 ± 0.69	6.59 ± 1.06	1/21	3/21	2/21	-	-	-	1/21	0
	Arm 1:18	No treatment	8.93 ± 1.12	9.05 ± 0.26	1/18	2/18	8/18	-	-	-	0	0
Li, 2003[35]	Arm 1:56	200 IU HBIG every 4 wk from week 28	7.38 ± 1.17	5.28 ± 2.77	3/56	7/56	-	-	-	-	0	0
	Arm 2:43	3TC 100 mg od from week 28	7.49 ± 0.54	5.33 ± 1.34	1/43	7/43	-	-	-	-	0	0
	Arm 3:52	No treatment	7.05 ± 1.29	6.23 ± 3.66	8/52	11/52	-	-	-	-	0	0

3TC: Lamivudine; HBIG: Hepatitis B immunoglobulin; IU: International unit; mg: Milligram; od: Once daily; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; -: Data not available.

¹Log₁₀ HBV DNA (mean ± SD).

Table 2 Methodological quality of included randomized clinical trials

First author, year^[Ref.]	Generation of allocation sequence	Allocation concealment	Blinding	Methodologicalquality
Han, 2010[22]	Unclear	Unclear	Unclear	Low
Zhang, 2010[21]	Unclear	Unclear	Unclear	Low
Han, 2009[23]	Unclear	Unclear	Unclear	Low
Su, 2009[24]	Unclear	Unclear	Unclear	Low
Xu, 2009[25]	Unclear	Adequate	Adequate	High
Shi, 2009[26]	Adequate	Adequate	Adequate	High
Yang, 2008[27]	Adequate	Unclear	Unclear	Low
Guo, 2008[28]	Adequate	Unclear	Unclear	Low
Xiang, 2007[29]	Adequate	Unclear	Unclear	Low
Feng, 2007[30]	Not done	Not done	Not done	Low
Li, 2006[31]	Not done	Not done	Not done	Low
Li, 2006[32]	Not done	Not done	Not done	Low
Han, 2005[33]	Not done	Not done	Not done	Low
Shi, 2005[34]	Adequate	Unclear	Unclear	Low
Li, 2003[35]	Adequate	Unclear	Unclear	Low

Citation: Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 2011; 17(38): 4321-4333
URL: https://www.wjgnet.com/1007-9327/full/v17/i38/4321.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i38.4321